Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best low volatility stocks to buy according to analysts. While keeping its ...

NRG Energy (NRG) stock falls after its 295MW Texas data center deal underwhelmed investors. Amgen (AMGN) stock dips as ...

Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Thousand Oaks-based Amgen saw shares dip about 5% on Aug. 6, the day after the company’s earnings announcement, though not because of the earnings themselves but rather about news of its weight-loss ...

If MariTide achieves 22-23% weight loss in the phase 3 trial and CagriSema and retatrutide are in the 24-27% range which I estimated based on the available phase 2 data, I do not believe that the ...

THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

In the Phase 2 study, MariTide demonstrated up to ~20% average weight loss in people living with obesity without Type 2 diabetes (T2D) compared with 2.6% in the placebo arm, and up to ~17% average ...

MariTide did not appear to outperform its competitors significantly. Zepbound showed slightly better results, peaking at an average weight loss of around 25% after a year’s worth of dosage, while ...